Provident Investment Management Inc. lowered its position in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) by 91.4% during the first quarter, Holdings Channel reports. The firm owned 35,676 shares of the medical equipment provider’s stock after selling 378,675 shares during the period. Zeltiq Aesthetics accounts for 0.4% of Provident Investment Management Inc.’s portfolio, making the stock its 24th largest position. Provident Investment Management Inc.’s holdings in Zeltiq Aesthetics were worth $1,984,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of ZLTQ. Ameritas Investment Partners Inc. bought a new position in shares of Zeltiq Aesthetics during the first quarter worth about $170,000. First Citizens Bank & Trust Co. bought a new position in shares of Zeltiq Aesthetics during the first quarter worth about $206,000. Peak Asset Management LLC bought a new position in shares of Zeltiq Aesthetics during the first quarter worth about $219,000. State of Alaska Department of Revenue boosted its position in shares of Zeltiq Aesthetics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 4,010 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 110 shares during the period. Finally, Princeton Alpha Management LP bought a new position in shares of Zeltiq Aesthetics during the first quarter worth about $223,000.
Zeltiq Aesthetics Inc (NASDAQ ZLTQ) remained flat at $56.48 during midday trading on Thursday. Zeltiq Aesthetics Inc has a 52 week low of $23.58 and a 52 week high of $56.50. The firm’s 50-day moving average is $56.05 and its 200-day moving average is $46.95.
A number of brokerages have issued reports on ZLTQ. Stifel Nicolaus cut Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a report on Thursday, March 2nd. Canaccord Genuity restated a “hold” rating and set a $56.50 target price on shares of Zeltiq Aesthetics in a report on Friday, March 10th. Zacks Investment Research upgraded Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a report on Wednesday, February 22nd. Finally, Aegis restated a “hold” rating and set a $56.00 target price on shares of Zeltiq Aesthetics in a report on Monday, April 24th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Zeltiq Aesthetics presently has an average rating of “Hold” and a consensus price target of $50.94.
Zeltiq Aesthetics Company Profile
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians.
Want to see what other hedge funds are holding ZLTQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zeltiq Aesthetics Inc (NASDAQ:ZLTQ).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/zeltiq-aesthetics-inc-zltq-shares-sold-by-provident-investment-management-inc/1932447.html
Receive News & Ratings for Zeltiq Aesthetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.